The content of this website is intended for United States audiences only.
LAST UPDATED
July 23 2024
Clinicaltrials.gov ID
EudraCT ID
A Phase 2/3 Study to Evaluate the Safety and Efficacy of Long-Acting Capsid Inhibitor GS-6207 in Combination With an Optimized Background Regimen in Heavily Treatment Experienced People Living With HIV-1 Infection With Multidrug Resistance (CAPELLA)
The primary objective of this study is to evaluate the antiviral activity of lenacapavir (formerly GS-6207) administered as an add-on to a failing regimen (functional monotherapy) in people with human immunodeficiency virus (HIV) (PWH) with multi-drug resistance (MDR).
View MoreAge
12 Years +
Sex
ALL
Healthy Volunteers
No
Medical Condition
HIV-1-infection
Gender
N/A
Date
November 2019 - October 2020
Study Type
INTERVENTIONAL
Study Phase
PHASE2, PHASE3
Product
Oral Lenacapavir, Oral Lenacapavir Placebo, Subcutaneous Lenacapavir, Failing ARV Regimen, Optimized Background Regimen (OBR)
Los Angeles, California, United States, 90036
Los Angeles, California, United States, 90069
Palm Springs, California, United States, 92264
Sacramento, California, United States, 95817
New Haven, Connecticut, United States, 06510
Washington, District of Columbia, United States, 20017
DeLand, Florida, United States, 32720
Fort Lauderdale, Florida, United States, 33316
Fort Pierce, Florida, United States, 34982
Hialeah, Florida, United States, 33016
Miami Beach, Florida, United States, 33139
Orlando, Florida, United States, 32803
Tampa, Florida, United States, 33614
West Palm Beach, Florida, United States, 33401
Atlanta, Georgia, United States, 30308
Atlanta, Georgia, United States, 30309
Savannah, Georgia, United States, 31401
Chicago, Illinois, United States, 60613
Chicago, Illinois, United States, 60657
Berkley, Michigan, United States, 48072
Saint Louis, Missouri, United States, 63139
Bronx, New York, United States, 10461
Flushing, New York, United States, 11355
Manhasset, New York, United States, 11030
Charlotte, North Carolina, United States, 28209
Philadelphia, Pennsylvania, United States, 19104
Providence, Rhode Island, United States, 02906
Memphis, Tennessee, United States, 38163
Austin, Texas, United States, 78705
Bellaire, Texas, United States, 77401
Dallas, Texas, United States, 75215
Dallas, Texas, United States, 75246
Houston, Texas, United States, 77098
Longview, Texas, United States, 75605
Annandale, Virginia, United States, 22003
Vancouver, British Columbia, Canada, V6Z 2C9
Toronto, Ontario, Canada, M5G 1K2
Montreal, Quebec, Canada, H2L 4E9
Ottawa, Canada, K1H 8L6
Santo Domingo, Dominican Republic, 10103
Santo Domingo, Dominican Republic, 10514
Marseille, France, 13009
Paris, France, 75010
Paris, France, 75012
Paris, France, 75018
Frankfurt, Hesse, Germany, 60590
Essen, Germany, 45122
Hamburg, Germany, 20146
Bergamo, Italy, 24127
Brescia, Italy, 25100
Milano, Italy, 20127
Roma, Italy, 00149
Rome, Italy, 00168
Nagoya, Japan, 460-0001
Osaka, Japan, 540-0006
Tokyo, Japan, 1600023
Tokyo, Japan, 1628655
Durban, South Africa, 4302
Johannesburg, South Africa, 2092
Pretoria, South Africa, 87
Soweto, South Africa, 2013
Badalona, Spain, 08916
Barcelona, Spain, 08036
Madrid, Spain, 28046
Sevilla, Spain, 41013
Kaohsiung, Taiwan, 80756
Kaohsiung, Taiwan, 81362
New Taipei City, Taiwan, 22060
Taipei, Taiwan, 10048
Taoyuan City, Taiwan, 33004
Bangkok, Thailand, 10330
Bangkok, Thailand, 10400
Bangkok, Thailand, 10700
Khon Kaen, Thailand, 40002
Nonthaburi, Thailand, 11000
Share Trial